David Waltz

VP and Head of CF Clinical Development
Vertex Pharmaceuticals Incorporated

Poster(s):

• (163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (185) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (694) Greater Reductions in Sweat Chloride with CFTR Modulator Use are Associated with Improved Clinical Outcomes
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET